Cantor Fitzgerald set a $17.00 price objective on Verastem (NASDAQ:VSTM) in a research report report published on Sunday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

VSTM has been the subject of several other reports. HC Wainwright restated a buy rating and set a $10.00 price objective on shares of Verastem in a research report on Wednesday, November 8th. Cann restated a buy rating and set a $15.00 price objective (up from $6.00) on shares of Verastem in a research report on Sunday. Oppenheimer restated a buy rating and set a $6.00 price objective on shares of Verastem in a research report on Thursday, October 12th. Zacks Investment Research cut shares of Verastem from a hold rating to a sell rating in a research report on Saturday, August 12th. Finally, ValuEngine cut shares of Verastem from a hold rating to a sell rating in a research report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $8.91.

Shares of Verastem (NASDAQ:VSTM) traded up $0.36 during midday trading on Friday, hitting $4.33. 1,286,800 shares of the stock were exchanged, compared to its average volume of 760,211. The company has a quick ratio of 3.12, a current ratio of 3.12 and a debt-to-equity ratio of 0.06. Verastem has a 1-year low of $1.08 and a 1-year high of $5.71.

Verastem (NASDAQ:VSTM) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.29). equities research analysts predict that Verastem will post -1.74 EPS for the current fiscal year.

In related news, Director Timothy J. Barberich bought 60,538 shares of the stock in a transaction on Tuesday, December 5th. The stock was bought at an average price of $3.95 per share, with a total value of $239,125.10. Following the completion of the purchase, the director now directly owns 130,000 shares in the company, valued at approximately $513,500. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.51% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of VSTM. Renaissance Technologies LLC boosted its stake in shares of Verastem by 20.0% in the first quarter. Renaissance Technologies LLC now owns 1,226,600 shares of the biopharmaceutical company’s stock valued at $2,539,000 after purchasing an additional 204,400 shares during the period. Alpine Woods Capital Investors LLC purchased a new position in shares of Verastem in the second quarter valued at approximately $109,000. Artal Group S.A. purchased a new position in shares of Verastem in the second quarter valued at approximately $1,090,000. Northern Trust Corp boosted its stake in shares of Verastem by 40.3% in the second quarter. Northern Trust Corp now owns 73,750 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 21,178 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Verastem by 10.3% in the second quarter. Vanguard Group Inc. now owns 1,143,642 shares of the biopharmaceutical company’s stock valued at $2,493,000 after purchasing an additional 107,029 shares during the period. 34.24% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Verastem (VSTM) Given a $17.00 Price Target at Cantor Fitzgerald” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/12/11/verastem-vstm-given-a-17-00-price-target-at-cantor-fitzgerald.html.

About Verastem

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Analyst Recommendations for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.